Related Experiment Videos
Partial agonist properties and toxicity of oral oxilorphan
Abstract:
Alternative pharmacologic adjuncts are needed for the management of opiate abuse. Oxilorphan, a narcotic antagonist, was studied at 5 different dose levels (1, 2, 4, 6, and 8 mg) in 30 normal subjects to determine the relation of single oral doses and toxicity. The drug causes pupillary constriction and mild central nervous system side effects (nausea, dizziness) at all doses. Mean urine volume increased (P less than 0.05) during the 12 hours after 1 and 2 mg. Oxilorphan has partial agonist properties similar to dl-cyclazocine.
Insights
Oxilorphan, a potential treatment for opiate abuse, was studied in normal subjects. This narcotic antagonist showed mild side effects and partial agonist properties, suggesting its potential as an alternative pharmacologic adjunct.
Area of Science:
- Pharmacology
- Addiction Medicine
- Clinical Toxicology
Background:
- Opiate abuse necessitates the development of alternative pharmacologic adjuncts.
- Narcotic antagonists are a key area of research for addiction management.
Purpose of the Study:
- To evaluate the safety and toxicity of single oral doses of oxilorphan.
- To determine the dose-response relationship of oxilorphan in normal subjects.
Main Methods:
- A single-dose, dose-escalation study was conducted.
- Thirty healthy subjects received oxilorphan at five dose levels (1, 2, 4, 6, and 8 mg).
- Adverse effects and physiological changes were monitored.
Main Results:
- Oxilorphan administration resulted in pupillary constriction.
- Mild central nervous system side effects, including nausea and dizziness, were observed across all doses.
- A statistically significant increase in mean urine volume was noted 12 hours post-administration for 1 mg and 2 mg doses (P < 0.05).
Conclusions:
- Oxilorphan exhibits partial agonist properties, similar to dl-cyclazocine.
- The study suggests oxilorphan's potential as an alternative pharmacologic adjunct for opiate abuse management.
- Further research is warranted to explore its therapeutic efficacy and safety profile.